Induction of tolerance through early introduction of peanut in high-risk children

ISRCTN ISRCTN94818122
DOI https://doi.org/10.1186/ISRCTN94818122
ClinicalTrials.gov number NCT00329784
Secondary identifying numbers ITN032AD Lack
Submission date
19/12/2006
Registration date
04/04/2007
Last edited
29/01/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
The number of children in the Western World that have a peanut allergy has doubled in the past ten years and the allergy is now also found in Africa and Asia. It is the leading course of food allergy related anaphylaxis (acute allergic reaction) and death. The allergy develops early in life and is generally life-long. Studies have suggested that the earlier peanuts are introduced to a childs diet, the less likely they are to develop an allergy to them. This study looks at whether giving children that are considered at higher risk of developing a peanut allergy (as they are already allergic to eggs or have severe eczema) earlier in life reduces the risk of them actually becoming allergic to peanuts.

Who can participate?
Children aged between 4 months and 11 months that have an egg allergy, severe eczema, or both.

What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group are fed a peanut-containing snack-food at least three times each week until they are 5 years old. Those in the second group avoid eating food containing peanuts until they are 5 years old. All the children are followed up to see which ones develop a peanut allergy.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Evelina Children's Hospital, London (UK)

When is the study starting and how long is it expected to run for?
November 2006 to July 2013

Who is funding the study?
1. US National Institute of Allergy & Infectious Diseases
2. Immune Tolerance Network (USA)
3. Food Allergy Initiative (USA)
4. Food Standards Agency (UK)

Who is the main contact?
Professor Gideon Lack
info@leapstudy.co.uk

Study website

Contact information

Prof Gideon Lack
Scientific

Evelina Children's Hospital
Guy's & St. Thomas' NHS Foundation Trust
Lambeth Palace Road
London
SE1 7EH
United Kingdom

Phone +44 (0)20 7188 9784
Email info@leapstudy.co.uk

Study information

Study designRandomised controlled single-site trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typePrevention
Participant information sheet Patient information can be found at: http://www.leapstudy.co.uk/participating.html
Scientific titleInduction of tolerance through early introduction of peanut in high-risk children
Study acronymLEAP (Learning Early About Peanut allergies)
Study hypothesisThis study will evaluate whether early avoidance or exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are at high risk as determined by allergy to eggs or severe eczema.
Ethics approval(s)St. Mary’s Research Ethics Committee, 23/10/2006, ref: 04/Q0413/13
ConditionPeanut allergy, peanut hypersensitivity, eczema, egg hypersensitivity, food hypersensitivity
InterventionParticipants assigned to the peanut consumption group will be fed at least 6 g of peanut protein per week, distributed over at least three meals per week during study participation. The preferred peanut source will be Bamba, however, peanut butter may be substituted. Participants assigned to the peanut avoidance group will avoid exposure to peanut protein during study participation.
Intervention typeSupplement
Primary outcome measureThe proportion of participants with peanut allergy at 60 months of age.
Secondary outcome measures1. Effect of peanut consumption on other allergy outcomes
2. Safety of peanut consumption among study participants
3. Immunologic mechanisms by which consumption of peanut may induce tolerance to peanuts
Overall study start date29/11/2006
Overall study end date01/07/2013

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit4 Months
Upper age limit11 Months
SexBoth
Target number of participants480
Participant inclusion criteria1. Children greater than four months and less than 11 months of age
2. Have had solid foods introduced successfully into their diet
3. Egg allergy, severe eczema or both
Participant exclusion criteria1. Clinically significant chronic illness, except for eczema or recurrent wheeze
2. Positive skin prick test for peanut allergen with a wheal diameter of greater than 4 mm
3. Previous or current consumption of peanut
4. Previous allergic reaction to peanut
5. Sibling or other household member who is allergic to peanut
6. Certain other immunological criteria
Recruitment start date29/11/2006
Recruitment end date01/07/2013

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Evelina Children's Hospital
London
SE1 7EH
United Kingdom

Sponsor information

Immune Tolerance Network for National Institute of Allergy and Infectious Diseases
Government

185 Berry Street
Suite 3515
San Francisco
94107
United States of America

Phone +1 415 353 4418
Email nnasser@immunetolerance.org
Website http://www.immunetolerance.org
ROR logo "ROR" https://ror.org/043z4tv69

Funders

Funder type

Government

US National Institute of Allergy & Infectious Diseases

No information available

Immune Tolerance Network (USA)

No information available

Food Allergy Initiative
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
FAI
Location
United States of America
Food Standards Agency
Private sector organisation / Other non-profit organizations
Alternative name(s)
The Food Standards Agency, FSA
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 26/02/2015 Yes No

Editorial Notes

29/01/2016: Publication reference added